Yükleniyor... / Loading...
This study examined the effects of physical activity and cognitive training interventions (Mind and Move) in older women with cardiovascular disease. It enrolled women aged 65 and older with a history of cardiovascular disease who did not engage in regular physical activity. This is a study without an assigned phase and has been completed.
The summary above is a plain-language rendering of the official record. The original English title is shown for reference.
Criteria are reproduced from the ClinicalTrials.gov record in the original English. Only the trial team can determine eligibility.
Inclusion Criteria: * self-identified as women * ≥ 65 years old * read/speak English * patient in the Rush Heart Center for Women * history of CVD (e.g., coronary artery disease, hypertension) and receiving guideline-directed medical therapy when appropriate * no regular moderate-vigorous physical activity (≥ 30 minutes ≥ 3 days per week in the past month) * no cognitive training program in the past month * no disabilities preventing regular physical activity (Physical Activity Readiness Questionnaire, which includes cardiac and lung disease symptoms) * written approval from cardiology provider (Physical Activity Readiness Medical Examination); no self-reported significant hearing loss that interferes with normal conversation * access to a Bluetooth-capable phone or tablet Exclusion Criteria: * symptoms of unstable cardiac or pulmonary disease in the past month (Physical Activity Readiness Questionnaire) * blood pressure (systolic ≥ 160 or diastolic ≥ 100 mm Hg) * cognitive status score \< 19 on the blind version (for phone administration) of the Montreal Cognitive Assessment (MoCA) consistent with significant cognitive impairment * diagnosis of a neurological disease found in the electronic health record (e.g., Alzheimer's disease dementia, Parkinson's disease, vascular dementia) * transient ischemic attack or small-vessel stroke in the past three months * taking anti-psychotic medication * diabetes with an A1C ≥ 9.0 within the past six months * end-stage renal disease on dialysis (Stage 5)